Cheshire-headquartered biotech company Centauri Therapeutics has received $5.1m (£3.8m) in funding to support the development of its lead compound.
Based in Alderley Park, Centauri specialises in immunotherapy drug discovery and is currently working on the development of its ABX-01 programme, a broad-spectrum antimicrobial selected to combat clinically prevalent drug-resistant bacteria.
In support of this, the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has provided the new funding.
“The unwavering scientific and financial support from CARB-X has provided stability to Centauri as a company, expanded understanding of our Alphamer platform, and enabled us to progress the ABX-01 programme from discovery, through early development, and is now providing a smooth and continuous path towards First in Human clinical studies,” said Dr. Jennifer Schneider, chief executive of Centauri Therapeutics.
“We are thankful for CARB-X and their continued engagement and confidence, which has allowed us to move a step closer to delivering a much needed therapeutic for serious, drug-resistant Gram-negative infections, even in the most clinically vulnerable patients.”
The latest round of funding brings the total amount provided to Centauri by CARB-X to $12.3m (£9.2m).
Dr. Erin Duffy, chief of research and development at CARB-X, commented: “We have been proud to support Centauri, beginning with answering key questions on the approach and continuing with the drug discovery that has led to the lead asset of ABX-01 and its progression towards building a dossier to support its advancement into first in human clinical trials.”
Register for Free
Bookmark your favorite posts, get daily updates, and enjoy an ad-reduced experience.
Already have an account? Log in
